Shots:

• The P-III DISCOVER-2a study involves assessing Tremfya (q4w/ q8w- SC) in bio-naïve patients with active PsA
• Results: @100wks. complete skin clearance (PASI 100) (59 %/53%); improvement in joint symptoms (ACR 20) (76%/74%). The findings confirmed that the robust efficacy of Tremfya demonstrated in patients @24wks. on physical function- physical aspects of health-related QoL- and resolution of enthesitisb and dactylitisc was also seen through 100wks.
• Additionally- the extent of radiographic progression was studied through 2yrs. Tremfya is the first and only IL-23 inhibitor therapy approved in the US to treat with active PsA and PsO

 ­ Ref: J&J | Image: Euro Finance